Dr. Mahadevan received his Bachelor of Science in physiology and biochemistry with chemistry from the University of Reading, England, in 1982. He went on to the University of London to earn his doctorate in protein crystallography in 1986. He received his Bachelor of Medicine, Bachelor of Surgery (M.D. equivalent) from King’s College Hospital Medical School at the University of London in 1990. He completed his residency in internal medicine at the University of Connecticut Health Center in 1997, and his hematology oncology fellowship at the University of Arizona Health Sciences Center in 2002. Dr. Mahadevan is board certified by the American Board of Internal Medicine and the American Board of Medical Oncology.
Dr. Mahadevan’s major area of clinical interest is early phase therapeutics in the treatment and management of patients with pancreatic cancer, gastrointestinal stromal tumors, myelodysplastic syndromes and non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia. He has a demonstrated track record of delivering first-in-human investigational agents for all oncology therapeutics and is a principal investigator or co-principal investigator on several National Institutes of Health and foundation grants. In addition, he has successfully directed a structure-based translational drug discovery laboratory program with the award of six U.S. patents for new drugs targeting novel driver oncogenes.